Compare TBLA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | ABCL |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | TBLA | ABCL |
|---|---|---|
| Price | $4.16 | $4.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.80 | ★ $7.75 |
| AVG Volume (30 Days) | 1.3M | ★ 4.8M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,880,771,000.00 | $35,325,000.00 |
| Revenue This Year | $11.31 | $25.45 |
| Revenue Next Year | $5.75 | $10.07 |
| P/E Ratio | $53.27 | ★ N/A |
| Revenue Growth | ★ 10.96 | 7.17 |
| 52 Week Low | $2.50 | $1.89 |
| 52 Week High | $4.65 | $6.52 |
| Indicator | TBLA | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 52.05 |
| Support Level | $4.02 | $3.92 |
| Resistance Level | $4.35 | $4.85 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 37.18 | 49.95 |
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.